

1 **Absence of Testicular Adrenal Rest Tumors in Newborns, Infants, and Toddlers with**
2 **Classical Congenital Adrenal Hyperplasia**

3 *Mimi S. Kim, Christina M. Koppin, Pankhuri Mohan, Fariba Goodarzian, Heather M. Ross,
4 Mitchell E. Geffner, Roger De Filippo, Paul Kokorowski

5 **Author Affiliations:**

6 Center for Endocrinology, Diabetes, and Metabolism, Children’s Hospital Los Angeles, Los
7 Angeles, California, United States of America (M.S.K., C.M.K., P.M., H.M.R., F.G., M.E.G.,
8 R.D., P.K.)

9 Keck School of Medicine of University of Southern California (M.S.K., F.G., M.E.G., R.D.,
10 P.K.)

11 The Saban Research Institute (M.S.K., M.E.G.)

12 Department of Radiology, Children’s Hospital Los Angeles (F.G.)

13 Division of Pediatric Urology, Children’s Hospital Los Angeles (R.D., P.K.)

14 **Running Head:** Testicular Adrenal Rest Tumors in Infants and Toddlers with CAH

15 ***Corresponding Author:** Mimi Kim, M.D., M.Sc.

16 Children’s Hospital Los Angeles

17 4650 Sunset Boulevard, Mailstop #61

18 Los Angeles, CA 90027

19 E-mail address: mskim@chla.usc.edu

20 Phone: +1 323-361-1358

21 **Keywords:** Newborn; Congenital Adrenal Hyperplasia; Ultrasonography; Testis; Adrenal rest
22 tissue

23 **Abstract**

24 **INTRODUCTION:** Testicular adrenal rest tumors (TART) are a known consequence for males
25 with classical congenital adrenal hyperplasia (CAH) due to 21-hydroxylase deficiency. TART
26 are associated with potential infertility in adults. However, little is known about TART in very
27 young males with CAH.

28 **OBJECTIVE:** We assessed the prevalence of TART in newborn, infant, and toddler males with
29 classical CAH via scrotal ultrasound.

30 **METHODS:** Males with CAH had scrotal ultrasounds during the first 4 years of life, evaluating
31 testes for morphology, blood flow, and presence of TART. Newborn screen 17-
32 hydroxyprogesterone (17-OHP) and serum 17-OHP at the time of ultrasound were recorded.
33 Bone ages were considered very advanced if $\geq 2SD$ above chronological age.

34 **RESULTS:** Thirty-one ultrasounds in 16 males were performed. An initial ultrasound was
35 obtained in four newborns at diagnosis (6.8 ± 2.1 days), six infants (2.2 ± 0.9 months), and six
36 toddlers (2.4 ± 0.9 years). Eleven males had at least one repeat ultrasound. A large proportion
37 (11/16) were in poor hormonal control with an elevated 17-OHP (325 ± 298 nmol/L). One infant
38 was in very poor hormonal control (17-OHP 447 nmol/L) at initial ultrasound, and two toddlers
39 had advanced bone ages (+3.2 and +4.5 SD) representing exposure to postnatal androgens.
40 However, no TART were detected in any subjects.

41 **CONCLUSIONS:** TART were not found in males up to 4 years of age with classical CAH
42 despite settings with expected high ACTH drive. Further research into the occurrence of TART
43 in CAH may elucidate factors which contribute to the detection and individual predisposition to
44 TART.

45 **Introduction**

46 Classical congenital adrenal hyperplasia (CAH) due to 21-hydroxylase deficiency is a
47 potentially life-threatening genetic cause of primary adrenal insufficiency characterized by
48 cortisol, aldosterone, and epinephrine deficiencies, as well as androgen excess. It is an autosomal
49 recessive disorder, characterized by a mutation in the *CYP21A2* gene which encodes the steroid
50 21-hydroxylase enzyme needed for the biosynthesis of cortisol and aldosterone [1, 2]. Since the
51 production of cortisol is hindered in CAH due to 21-hydroxylase deficiency, there is a loss of
52 negative feedback to the hypothalamus/pituitary gland and subsequent ACTH hyperstimulation
53 ensues. These high levels of ACTH in CAH patients have been shown to have deleterious effects
54 and may contribute to the development of testicular adrenal rest tumors (TART).

55 In an individual who develops TART, one would expect the ectopic adrenal tissue to be
56 present from the earliest moments of gonadal development [3, 4]. Testicular adrenal rest cells
57 originate from adrenal cells which migrate with primitive gonadal cells from the urogenital ridge
58 at approximately the eighth week of fetal development [5]. As a result, adrenal rest cells in males
59 may come to reside within the testicles in prenatal life and ultimately reside anywhere along the
60 path of their descent [6].

61 TART are a well-known potential complication of CAH in males. They can become large
62 testicular masses causing compressive irreversible damage to the testicular parenchyma,
63 ultimately leading to fibrosis, decreased spermatogenesis, and decreased germ cells as seen on
64 biopsy specimens of patients [7, 8]. Localizing the position of the tumors and determining the
65 size may help determine a fertility prognosis. Patients with TART also have higher
66 concentrations of steroid production including 17-hydroxyprogesterone and androstenedione [9].
67 Identifying the tumor early can allow physicians to focus on treatment regimens to prevent
68 infertility and control potential ectopic steroid production.

69 TART have been reported in adults and children as young as 4.1 years old by ultrasound,
70 with a prevalence of 44% in adults and 21-33% in childhood [7, 10, 11]. At our center, TART
71 have been diagnosed in males as young as 6 years old. TART was detected in 1/9 (11%) of
72 patients 5-12 years old, and 4/19 (21%) of patients older than 12 years old [12]. Historically, we
73 know that histological evidence of TART can be found in post-mortem infants as young as 8
74 weeks old [3]. However, there is little known about the prevalence of TART in male newborns,
75 infants, or toddlers with CAH.

76 Therefore, the aim of our study was to determine the prevalence of TART by scrotal
77 ultrasound in newborn, infant, and toddler males with CAH due to 21-hydroxylase deficiency at
78 a tertiary referral center for CAH. We hypothesized that TART would only be found in those
79 with extremely poor hormonal control in this very young age group.

80 **Participants and Methods**

81 *Study Participants*

82 Subjects were recruited from our tertiary referral center for CAH. Inclusion criteria
83 consisted of male sex with classical CAH due to 21-hydroxylase deficiency confirmed by
84 biochemical and/or genetic testing, including newborns (< 1 month old), infants (1 to 12 months
85 old), and toddlers (older than 12 months up to 4 years old). Exclusion criteria consisted of female
86 sex, CAH not due to 21-hydroxylase deficiency, or age ≥ 4 years.

87 *Study Design*

88 Scrotal ultrasounds (14-MHz linear array transducer) were performed prior to the age of
89 4 years. Testes were evaluated for morphology and blood flow, with particular emphasis on
90 examining for the presence of lesions consistent with TART. Newborn screening for CAH, via
91 elevations in 17-hydroxyprogesterone (17-OHP), is state mandated in California and has an

92 estimated sensitivity of 98.5% and specificity of 99.9%, with activation cut-offs stratified by
93 weight and gestational age. Newborn screening 17-OHP levels were recorded as a measure of
94 disease severity at birth, and serum 17-OHP and androgen (testosterone and androstenedione)
95 levels closest to time of imaging were recorded as measures of hormonal control.

96 The most recent hydrocortisone replacement dose ($\text{mg}/\text{m}^2/\text{day}$) each subject maintained
97 for at least three weeks prior to the time of ultrasound was recorded. Hydrocortisone replacement
98 dose was not recorded for subjects without a stable dose for at least three weeks prior to the time
99 of ultrasound.

100 Bone age was assessed in subjects when there was clinical concern, using a left hand x-
101 ray to examine for signs of epiphyseal maturation, and read by a pediatric endocrinologist
102 (M.S.K.). Bone age was not routinely performed in our young cohort of infants and toddlers. A
103 bone age more than two standard deviations from chronological age were considered to be very
104 advanced.

105 Descriptive statistics are presented as mean \pm SD.

106 **Results**

107 *Study Population*

108 Sixteen males with CAH due to 21-hydroxylase deficiency were studied. Fifteen males
109 had the salt-wasting form and one had the simple-virilizing form. At the time of ultrasound,
110 average hydrocortisone doses were $29.5 \pm 11.4 \text{ mg}/\text{m}^2/\text{day}$ for infants less than six months, 17.1
111 $\pm 7.4 \text{ mg}/\text{m}^2/\text{day}$ for infants greater than six months, and $13.0 \pm 4.1 \text{ mg}/\text{m}^2/\text{day}$ for toddlers. The
112 average newborn screen 17-OHP for all participants was $424 \pm 206 \text{ nmol}/\text{L}$ (range 73 – 800).

113 *Scrotal Ultrasound*

114 Thirty one ultrasounds were performed on 16 males. Eleven of 16 males had at least one
115 repeat ultrasound up until 4 years of life. Four newborns had an initial ultrasound at CAH
116 diagnosis; their mean newborn screen 17-OHP was 395 ± 180 nmol/L. Six infants (age 1 to 12
117 months old) had an initial ultrasound prior to 4 months of age. One male infant was in very poor
118 hormonal control in (17-OHP was 447 nmol/L at the time of the initial ultrasound), but remained
119 TART-negative on two additional ultrasounds at 7.5 and 13.6 months of age despite having an
120 increase in 17-OHP to 1,025 nmol/L, and very advanced bone age (+3.2 SD). Six toddlers had
121 their initial ultrasound between 1 and 4 years of age. One toddler also had a very advanced bone
122 age (+4.5 SD), likely representing substantial exposure to postnatal androgens, but did not
123 exhibit TART on ultrasound. At the time of the ultrasounds, a large proportion of males were in
124 poor hormonal control, with 11 of 16 males exhibiting a considerably elevated 17-OHP of $325 \pm$
125 298 nmol/L despite being on high doses of hydrocortisone in most cases.

126 Overall, no TART were detected on any scrotal ultrasounds. Normal testicular
127 morphology and blood flow were noted in all subjects.

128 **Discussion/Conclusion**

129 In this study we looked for the presence of TART in males as young as newborns with
130 repeated ultrasounds throughout the first four years of life. No TART were detected by
131 ultrasound in males with classical CAH up to 4 years of life, including newborns at the time of
132 diagnosis, infants, and toddlers. Despite high serum 17-OHP levels at birth and poor hormonal
133 control in 11 of 16 subjects, including two toddlers with very advanced bone ages, ultrasound
134 screening for TART remained negative in our cohort. Although we did not measure plasma
135 ACTH in the study subjects, it can be inferred that plasma concentrations would be high given
136 the magnitude of the 17-OHP concentrations in many of the boys. Our results suggest that poor

137 hormonal control, or high ACTH levels alone, do not seem to be sufficient to drive the growth of
138 detectable adrenal rest tumors in this age group [11]. However, our negative findings could also
139 simply be a result of an absence of adrenal rest tissue.

140 The prevalence of TART in males has been estimated to be 33% in boys and 44% in men
141 with classical CAH [10, 13]. Although the prevalence of TART is lower in pediatric patients,
142 several investigators have noticed the presence of TART in males as young as 4.1 years, 6.2
143 years, and 7.5 years of age [7, 10, 14]. Furthermore, newborns with CAH have significantly lower
144 cortisol concentrations with compensatory elevation of plasma ACTH levels, which should
145 theoretically promote growth of adrenal rest tissue and lead to development of TART [3, 15].
146 ACTH levels have been previously correlated to the prevalence of TART in adult males [16].
147 One possible explanation for the decreased prevalence of TART in pediatric patients, however, is
148 that a prolonged postnatal duration of exposure to elevated ACTH levels is important in
149 stimulating the growth of TART [17]. The role of ACTH is supported by the finding that early-
150 stage TART can regress with high-dose glucocorticoid therapy. Furthermore, TART can be
151 present in males with poorly controlled Addison disease [18] and in the ovaries and/or para-
152 ovarian regions in females with poorly controlled CAH [19]. Further research on the presence of
153 TART in ectopic ACTH syndromes (small cell lung cancers, islet cell tumors, etc.) could
154 reinforce the theory that ACTH influences TART theory development.

155 The importance of early detection of TART has several advantages. First, the prevalence
156 of TART in a newborn or infant could indicate a high ACTH concentration *in utero*, which could
157 provide a CAH disease severity measure. Secondly, TART are a well-known comorbidity in
158 males with CAH and can cause infertility and severe pain due to the compression of the testicular
159 parenchyma. Patients with TART are counseled to consider infertility as a possible consequence

160 and cryopreservation of sperm may be recommended to these patients in the earlier stages of
161 tumor development. While these are consequences of long-standing TART, early identification
162 may aid in addressing the tumor at a preliminary stage as several case studies have reported the
163 use of intensified glucocorticoid treatments to prevent growth and promote regression of these
164 tumors [9].

165 Autopsy studies suggest that the prevalence of adrenal rest cells is variable. One of the
166 earliest reports suggests that ectopic adrenal tissue can be found on autopsy in 50% of healthy
167 neonates and children [20]. Other autopsy studies have found aberrant adrenal tissue in 7.5% of
168 individuals as an ovoid mass near the testes, with 1.5% located close to the rete testes [4].
169 Furthermore, ectopic adrenal tissue during exploration for hernia repairs has been noted in 2.7%
170 of cases [21]. A study of 89 deceased male neonates, without CAH and specifically examining
171 the testes, found that only 4 out of 115 (3.5%) contained TART and only one of these near the
172 rete testis [7]. By contrast, another study found adrenal nodules on autopsy in the testes of 43%
173 (3/7) of male CAH infants less than eight weeks of age and 100% (n=14) children less than 14
174 months of age [3]. This seems to suggest that while adrenal tissue is uncommonly found in the
175 testes, there could be undetectable progenitor cells that require further stimulus to be able to
176 grow to detectable levels. Hence the prevalence and natural course of regression of testicular
177 adrenal rest tissue in infants with CAH merits further research and could yield an increased
178 understanding of the mechanisms that promote tumor formation in some but not others. Overall,
179 a more in-depth understanding of TART in male infants and toddlers with and without CAH
180 could help inform future clinical screening guidelines.

181 Our study results should be interpreted in light of certain limitations. It is unclear whether
182 the lack of detection of TART in our cohort is related to the limited sensitivity of

183 ultrasonography or if TART are simply absent in these patients. Furthermore, our sample size is
184 small with limited power to detect a small prevalence of TART. A larger cohort of very young
185 males with CAH could allow us to better characterize the absence or presumed very low
186 prevalence of TART. Finally, temporal variation in hormonal control cannot be captured with
187 our available serum test results and could result in misclassification of those in good versus poor
188 control.

189 In conclusion, TART can be a clinically significant co-morbidity in males with CAH. In
190 our study, TART were not detected by ultrasonography in very young males up to 4 years of age
191 with classical CAH, despite conditions of high ACTH drive at birth and pre-treatment, and
192 conditions of poor hormonal control while on treatment. Further study is needed to understand
193 individual predisposition to TART, the regression of testicular adrenal rest cells in infants, and
194 the sensitivity of imaging modalities in the detection of TART.

195 **Statements**

196 **Acknowledgments**

197 We gratefully thank the patients and families at our center for their participation, Janet Guerrero
198 (CAH Clinic Coordinator), and CARES Foundation for support of the CAH Comprehensive
199 Care Center at Children’s Hospital Los Angeles.

200 **Statement of Ethics**

201 The study was reviewed and approved by the Children’s Hospital Los Angeles institutional
202 review board (CCI-13-00239 TART and CAH; CCI-12-0020 Natural History Study of CAH
203 from Infancy). Parents gave written informed consent in accordance with the World Medical
204 Association Declaration of Helsinki.

205 **Disclosure Statement**

206 Mitchell E. Geffner serves as an advisor to Daiichi Sankyo, Novo Nordisk, Nutrition & Growth
207 Solutions, Pfizer, and Spruce Biosciences; on data safety monitoring boards for Ascendis and
208 Tolmar; and receives royalties from McGraw-Hill and UpToDate.

209 **Funding Sources**

210 This work was supported by CARES Foundation (MSK and MEG) and the Abell Foundation
211 (MEG). The writing of this paper was funded by K23 HD084735-01A1 (MSK).

212 **Author Contributions**

213 Mimi S. Kim, Paul Kokorowski, and Mitchell E. Geffner conceptualized and designed the study.
214 Fariba Goodarzian performed analysis of ultrasound data and Christina M. Koppin, Pankhuri
215 Mohan, and Heather M. Ross collected the data. Mimi S. Kim and Christina M. Koppin drafted
216 the initial manuscript. All authors critically reviewed the manuscript and approved of the final
217 manuscript as submitted.

218 **References**

- 219 1. Auchus RJ, Witchel SF, Leight KR, Aisenberg J, Azziz R, Bachega TA, et al. Guidelines for
220 the development of comprehensive care centers for congenital adrenal hyperplasia: Guidance
221 from the CARES Foundation Initiative. *Int J Pediatr Endocrinol.* 2010;2010:1-7.
- 222 2. Kim MS, Ryabets-Lienhard A, Bali B, Lane CJ, Park AH, Hall S, et al. Decreased
223 adrenomedullary function in infants with classical congenital adrenal hyperplasia. *J Clin*
224 *Endocrinol Metab.* 2014;99(8):E1597-601.
- 225 3. Shanklin DR, Richardson AP, Jr., Rothstein G. Testicular hilar nodules in adrenogenital
226 syndrome. The nature of the nodules. *Am J Dis Child.* 1963;106:243-50.
- 227 4. Bouman A, Hulsbergen-van de Kaa C, Claahsen-van der Grinten HL. Prevalence of testicular
228 adrenal rest tissue in neonates. *Horm Res Paediatr.* 2011;75(2):90-3.
- 229 5. Stikkelbroeck NM, Otten BJ, Pasic A, Jager GJ, Sweep CG, Noordam K, et al. High
230 prevalence of testicular adrenal rest tumors, impaired spermatogenesis, and Leydig cell failure in
231 adolescent and adult males with congenital adrenal hyperplasia. *J Clin Endocrinol Metab.*
232 2001;86(12):5721-8.
- 233 6. Verhees MJM, Kamphuis-Van Ulzen K, Hermus A, Stikkelbroeck N, Mooij CF, Claahsen-
234 van der Grinten HL. Re: Testicular Adrenal Rest Tumors in Boys and Young Adults with
235 Congenital Adrenal Hyperplasia: M. S. Kim, F. Goodarzian, M. F. Keenan, M. E. Geffner, C. M.
236 Koppin, R. E. De Filippo and P. J. Kokorowski *J Urol* 2017;197:931-936. *J Urol.*
237 2018;199(5):1357-8.
- 238 7. Claahsen-van der Grinten HL, Sweep FC, Blickman JG, Hermus AR, Otten BJ. Prevalence of
239 testicular adrenal rest tumours in male children with congenital adrenal hyperplasia due to 21-
240 hydroxylase deficiency. *Eur J Endocrinol.* 2007;157(3):339-44.

- 241 8. Seidenwurm D, Smathers RL, Kan P, Hoffman A. Intratesticular adrenal rests diagnosed by
242 ultrasound. *Radiology*. 1985;155(2):479-81.
- 243 9. Engels M, Span PN, van Herwaarden AE, Sweep F, Stikkelbroeck N, Claahsen-van der
244 Grinten HL. Testicular adrenal rest tumors: current insights on prevalence, characteristics, origin
245 and treatment. *Endocr Rev*. 2019;40(4):973-987.
- 246 10. Finkelstein GP, Kim MS, Sinaii N, Nishitani M, Van Ryzin C, Hill SC, et al. Clinical
247 characteristics of a cohort of 244 patients with congenital adrenal hyperplasia. *J Clin Endocrinol*
248 *Metab*. 2012;97(12):4429-38.
- 249 11. Claahsen-van der Grinten HL, Hermus AR, Otten BJ. Testicular adrenal rest tumours in
250 congenital adrenal hyperplasia. *Int J Pediatr Endocrinol*. 2009;2009:624823.
- 251 12. Kim MS, Goodarzian F, Keenan MF, Geffner ME, Koppin CM, De Filippo RE, et al.
252 Testicular Adrenal Rest Tumors in Boys and Young Adults with Congenital Adrenal
253 Hyperplasia. *J Urol*. 2017;197(3 Pt 2):931-6.
- 254 13. Mendes-Dos-Santos CT, Martins DL, Guerra-Junior G, Baptista MTM, de-Mello MP, de
255 Oliveira LC, et al. Prevalence of Testicular Adrenal Rest Tumor and Factors Associated with Its
256 Development in Congenital Adrenal Hyperplasia. *Horm Res Paediatr*. 2018;90(3):161-8.
- 257 14. Mouritsen A, Jorgensen N, Main KM, Schwartz M, Juul A. Testicular adrenal rest tumours
258 in boys, adolescents and adult men with congenital adrenal hyperplasia may be associated with
259 the CYP21A2 mutation. *Int J Androl*. 2010;33(3):521-7.
- 260 15. Stikkelbroeck NM, Suliman HM, Otten BJ, Hermus AR, Blickman JG, Jager GJ. Testicular
261 adrenal rest tumours in postpubertal males with congenital adrenal hyperplasia: sonographic and
262 MR features. *Eur Radiol*. 2003;13(7):1597-603.

- 263 16. Mazzilli R, Stigliano A, Delfino M, Olana S, Zamponi V, Iorio C, et al. The High
264 Prevalence of Testicular Adrenal Rest Tumors in Adult Men With Congenital Adrenal
265 Hyperplasia Is Correlated With ACTH Levels. *Front Endocrinol.* 2019;10:335.
- 266 17. Claahsen-van der Grinten HL, Otten BJ, Hermus AR, Sweep FC, Hulsbergen-van de Kaa
267 CA. Testicular adrenal rest tumors in patients with congenital adrenal hyperplasia can cause
268 severe testicular damage. *Fertil Steril.* 2008;89(3):597-601.
- 269 18. Sisto JM, Liu FW, Geffner ME, Berman ML. Para-ovarian adrenal rest tumors: gynecologic
270 manifestations of untreated congenital adrenal hyperplasia. *Gynecol Endocrinol.* 2018;34(8):644-
271 6.
- 272 19. Schwarz E, Liu AP, Randall H, Haslip C, Keune F, Murray M, et al. Use of Steroid Profiling
273 by UPLC-MS/MS as a Second Tier Test in Newborn Screening for Congenital Adrenal
274 Hyperplasia: The Utah Experience. *Pediatr Res.* 2009;66(2):230-5.
- 275 20. Jayarajah U, Herath KB, Fernando MH, de Silva VC, Goonewardena S. Testicular adrenal
276 rest tumour in an adult patient with congenital adrenal hyperplasia: a case report and review of
277 literature. *J Surg Case Rep.* 2018;2018(10):4.
- 278 21. Sullivan JG, Gohel M, Kinder RB. Ectopic adrenocortical tissue found at groin exploration
279 in children: incidence in relation to diagnosis, age and sex. *BJU Int.* 2005;95(3):407-10.

280 **Table 1. Scrotal Ultrasounds in Newborns, Infants, and Toddlers with Classical Congenital**

281 **Adrenal Hyperplasia**

CAH Type	Newborn 17-OHP (nmol/L)	Age at ultrasound (months)	17-OHP at ultrasound (nmol/L)	Hydrocortisone dose at ultrasound (mg/m ² /day)	Advanced Bone Age (> 2 SD)
SV	73	US1: 25.5	US1: 73	US1: 10.9	N/A
SW	170	US1: 0.3 US2: 18.5	US 1: 272 US2: 188	US1: Newborn US2: 18.2	N/A
SW	183	US1: 1.5 US2: 22.5 US3: 35.4	US1: 2.0 US2: 1.8 US3: 135	US1: 19.0 US2: 11.7 US3: 11.8	N/A
SW	277	US1: 3.7 US2: 7.5 US3: 13.6	US1: 447 US2: 9.7 US3: 1025	US1: 19.4 US2: 25.6 US3: 21.7	Yes
SW	281	US1: 25.2 US2: 43.5	US1: 39 US2: 43	US1: 13.9 US2: 13.5	No
SW	340	US1: 0.2	US 1: 163	US1: Newborn	N/A
SW	363	US1: 46.4	US1: 1.4	US1: 20.3	Yes
SW	394	US1: 0.3 US2: 10.4	US1: 868 US2: 3.8	US1: Newborn US2: 13.2	N/A
SW	406	US1: 0.2 US2: 11.0	US1: 663 US2: 2.2	US1: Newborn US2: 11.6	N/A
SW	492	US1: 26.8 US2: 33.3	US1: 4.0 US2: 104	US1: 6.3 US2: 10	No
SW	502	US1: 31.6	US1: 15	US1: 9.8	N/A
SW	550	US1: 14.2 US2: 46.4	US1: 28 US2: 150	US1: 17.9 US2: 11.1	No
SW	611	US1: 1.0 US2: 17.2	US 1: 48 US2: 264	US1: 40.0 US2: 13.0	N/A
SW	631	US1: 1.8	US1: 1.3	US1: 41.7	N/A
SW	712	US1: 1.5 US2: 23.9	US1: 33 US2 : <0.2	US1: 19.0 US2: 9.0	N/A
SW	808	US1: 2.4 US2: 23.3 US3: 33.3	US1: 4.1 US2: 274 US3: 205	US1: 38 US2: 11.6 US3: 13.9	No

282 17-OHP, 17-hydroxyprogesterone; CAH, congenital adrenal hyperplasia; SV, simple-virilizing;
 283 SW, salt-wasting
 284 Hydrocortisone dose: At the time of ultrasound, subject was on the dose for less than three
 285 weeks. Newborns were not on a daily dose of hydrocortisone.